Abrogation of chronic monoclonal antibody treatment-induced T-cell exhaustion with DURVALUMAB (MEDI4736) in advanced HER-2 negative breast cancer: a pilot proof-of-concept trial.

Trial Profile

Abrogation of chronic monoclonal antibody treatment-induced T-cell exhaustion with DURVALUMAB (MEDI4736) in advanced HER-2 negative breast cancer: a pilot proof-of-concept trial.

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Durvalumab (Primary) ; Bevacizumab
  • Indications Advanced breast cancer
  • Focus Pharmacodynamics; Proof of concept
  • Most Recent Events

    • 13 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
    • 13 Sep 2017 Planned primary completion date changed from 1 Jan 2018 to 1 May 2018.
    • 13 Sep 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top